Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,655
Views
4
CrossRef citations to date
0
Altmetric
Review

IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

Karsten A. Pilonesa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-0982-3260View further author information
ORCID Icon,
Maud Charpentiera Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USAORCID Iconhttps://orcid.org/0000-0002-7343-4163View further author information
ORCID Icon,
Elena Garcia-Martinezb Hematology and Oncology Department, Hospital Universitario Morales Meseguer, Murcia, SpainView further author information
&
Sandra Demariaa Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA;c Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4426-0499View further author information
ORCID Icon
Article: 1790716 | Received 28 Jun 2020, Accepted 29 Jun 2020, Published online: 09 Jul 2020

References

  • Garcia-Martinez E, Smith M, Buque A, Aranda F, de la Pena FA, Ivars A, Canovas MS, Conesa MAV, Fucikova J, Spisek R, et al. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology. 2018;7:e1433982. doi:10.1080/2162402X.2018.1433982.
  • Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008;222:357–2. doi:10.1111/j.1600-065X.2008.00604.x.
  • Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HEK, Thompson JA, Sondel PM, Wakelee HA, Disis ML, Kaiser JC, et al. A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors. Clin Cancer Res. 2018;24:1525–1535. doi:10.1158/1078-0432.CCR-17-2451.
  • Steel JC, Waldmann TA, Morris JC. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci. 2012;33:35–41. doi:10.1016/j.tips.2011.09.004.
  • Bergamaschi C, Pandit H, Nagy BA, Stellas D, Jensen SM, Bear J, Cam M, Valentin A, Fox BA, Felber BK, et al. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10. J Immunother Cancer. 2020;8:e000599. doi:10.1136/jitc-2020-000599.
  • Bottcher JP, Reis ESC. The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity. Trends Cancer. 2018;4:784–792. doi:10.1016/j.trecan.2018.09.001.
  • Pilones KA, Charpentier M, Garcia-Martinez E, Daviaud C, Kraynak J, Aryankalayil J, Formenti SC, Demaria S. Radiotherapy cooperates with IL15 to induce antitumor immune responses. Cancer Immunol Res OnlineFirst June. 2020;12:2020. doi:10.1158/2326-6066.CIR-1119-0338.
  • Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, et al. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2018;24:5552–5561. doi:10.1158/1078-0432.CCR-18-0945.
  • Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618. doi:10.1038/ncomms15618.
  • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. doi:10.1016/j.immuni.2013.07.012.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.